Dr. Jonathan Brodie
Add to your Care-Team
Dr. Jonathan Brodie
Dr. Jonathan Brodie
New York, NY
I specialize in
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I am located at
New York , NY
155 EAST 38 STREET
New York , NY 10016
Accepted Insurance Plans
I was educated and trained at
Medical / Graduate School
New York University School of Medicine
University of Wisconsin
Dr. Jonathan Brodie M
I've won the following awards
Top Doctors, Castle Connolly Medical
Top Doctor, Super Doctors
Best Doctors in New York, New York Magazine
Solomon Berson Distinguished Alumni Award, NYU School of Medicine
Senior Investigator Award, NARSAD
(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent Î³-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.
J. Med. Chem., Jan;55(1):357-66 (2012)
Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees.
Am J Psychiatry., Nov;166(11):1269-77 (2009)
Cue-induced dopamine release predicts cocaine preference: positron emission tomography studies in freely moving rodents.
J. Neurosci., May;29(19):6176-85 (2009)
Racemic gamma vinyl-GABA (R,S-GVG) blocks methamphetamine-triggered reinstatement of conditioned place preference.
Synapse., Feb;63(2):87-94 (2009)
Subchronic racemic gamma vinyl-GABA produces weight loss in Sprague Dawley and Zucker fatty rats.
Synapse., Nov;62(11):870-2 (2008)
Gamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism.
Drug Alcohol Depend., Oct;97(3):216-25 (2008)
The brain and behavior: limitations in the legal use of functional magnetic resonance imaging.
Am J Law Med., 33(2-3):271-94 (2007)
Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results.
Arch. Ophthalmol., Sep;124(9):1257-62 (2006)
Metabolic correlates of toluene abuse: decline and recovery of function in adolescent animals.
Psychopharmacology (Berl.)., Jun;186(2):159-67 (2006)
Imaging addiction with PET: is insight in sight?
Drug Discov. Today., Apr;10(8):547-62 (2005)
Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction.
Synapse., Feb;55(2):122-5 (2005)
Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA.
Synapse., Dec;50(3):261-5 (2003)
Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission.
Neuropsychopharmacology., Nov;25(5):704-12 (2001)
Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study.
Life Sci., Feb;66(13):PL169-73 (2000)
Functional magnetic resonance imaging of human brain activity in a verbal fluency task.
J. Neurol. Neurosurg. Psychiatr., Apr;64(4):492-8 (1998)
Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
Am J Psychiatry., Mar;155(3):337-43 (1998)
Long-term stability of neurotransmitter activity investigated with 11C-raclopride PET.
Synapse., Jan;28(1):66-70 (1998)
Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.
Neuropsychopharmacology., Jan;18(1):18-25 (1998)
GABAergic attenuation of cocaine-induced dopamine release and locomotor activity.
Synapse., Apr;25(4):393-8 (1997)
Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects.
Am J Psychiatry., Apr;154(4):490-6 (1997)
The study of neurotransmitter interactions using positron emission tomography and functional coupling.
Clin Neuropharmacol., Oct;19(5):371-89 (1996)
Time-dependent effects of a haloperidol challenge on energy metabolism in the normal human brain.
Psychiatry Res., Mar;60(2-3):91-9 (1996)
Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
Am J Psychiatry., Mar;153(3):346-54 (1996)
Imaging for the clinical psychiatrist: facts, fantasies, and other musings.
Am J Psychiatry., Feb;153(2):145-9 (1996)
Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis.
J. Neurosci., Jan;15(1 Pt 2):821-9 (1995)
Haloperidol blocks the uptake of [18F]N-methylspiroperidol by extrastriatal dopamine receptors in schizophrenic patients.
Synapse., Jan;19(1):14-7 (1995)
Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology.
Biol. Psychiatry., Sep;36(5):317-25 (1994)
Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects.
Am J Psychiatry., May;151(5):681-6 (1994)
Diminished cerebral metabolic response to motor stimulation in schizophrenics: a PET study.
Eur Arch Psychiatry Clin Neurosci., 244(3):115-25 (1994)
Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.
Proc. Natl. Acad. Sci. U.S.A., Dec;90(24):11816-20 (1993)
Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels.
Synapse., Apr;13(4):350-6 (1993)
Negative symptoms and hypofrontality in chronic schizophrenia.
Arch. Gen. Psychiatry., Dec;49(12):959-65 (1992)
Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons.
Synapse., Nov;9(3):195-207 (1991)
Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.
Psychiatry Res., Oct;40(2):115-24 (1991)
Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia.
Psychiatry Res., May;40(1):11-20 (1991)
Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET).
Synapse., Apr;7(4):324-7 (1991)
Positron emission tomography (PET) studies of dopaminergic/cholinergic interactions in the baboon brain.
Synapse., 6(4):321-7 (1990)
Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.
Am J Psychiatry., Jul;146(7):905-8 (1989)
The metabolic centroid method for PET brain image analysis.
J. Cereb. Blood Flow Metab., Jun;9(3):388-97 (1989)
Dopamine receptor occupancy and plasma haloperidol levels.
Arch. Gen. Psychiatry., May;46(5):482-4 (1989)
Reproducibility of cerebral glucose metabolic measurements in resting human subjects.
J. Cereb. Blood Flow Metab., Aug;8(4):502-12 (1988)
Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.
Biol. Psychiatry., Apr;23(7):653-63 (1988)
Low frontal glucose utilization in chronic schizophrenia: a replication study.
Am J Psychiatry., Feb;145(2):251-3 (1988)
Regional glucose metabolism in chronic schizophrenia.
Am J Physiol Imaging., 3(1):54 (1988)
Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration.
J. Neurol. Neurosurg. Psychiatr., Oct;49(10):1199-1202 (1986)
Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography.
Am J Psychiatry., May;142(5):564-71 (1985)
Patterns of metabolic activity in the treatment of schizophrenia.
Ann. Neurol., 15 Suppl:S166-9 (1984)
Dr. Jonathan Brodie M